Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Director of Swiss hospital describes the rush to treat the injured from Alpine resort bar fire - 2Israeli forces kill one person in series of attacks on southern Lebanon
- 3Figure out how to Put resources into Lab Precious stones: A Novice's Aide
- 4Whale stranded off Germany for days free again
- 5The Ursid meteor shower will be the last of the year, peaking just before Christmas: What to know and how to watch
- Beyond oil: The crucial exports blocked by Hormuz closure
- Closets for Your Room: Plan and Utility Features
- UN rights chief: Israel's new Gaza aid agency rules 'outrageous'
- 100 new alien worlds: Scientists find hidden haul in data from NASA exoplanet-hunting spacecraft
- Philippines evacuates 3,000 villagers after volcano activity raises alert level
- 8 Espresso Bean Starting points All over the Planet
- 6 Solid Vehicle Fix Administrations to Keep Your Vehicle in Prime Condition
- Ski Resorts Universally: A Colder time of year Wonderland Guide
- 2 ways you can conserve the water used to make your food
